Excited to announce that Adovate will be attending the 43rd Annual J.P. Morgan Healthcare Conference and RESI JPM 2025 in San Francisco, CA, from January 12-16, 2025! Join us to learn more about how Adovate is transforming innovation in adenosine-based therapeutics. Our CEO and Chairman, Bill Stilley, and CFO, Uday Gupta, are looking forward to connecting with industry leaders, investors, and innovators to share insights and explore potential collaborations. 📅 Let's make meaningful connections! If you’ll be attending, don’t hesitate to reach out. Learn more about us at www.adovate.com. #JPM2025 #HealthcareInnovation #RESIConference #Biotech #Pharma #Collaboration #Adovate
About us
Adovate develops novel drugs that target adenosine receptors involved in major diseases. These drug candidates have been created using our next-generation adenosine drug development platform, which enable design of patented compounds with favorable physiochemical characteristics and distribution kinetics that historically limited drugs acting against the adenosine receptors.
- Website
-
www.adovate.com
External link for Adovate
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Charlottesville, VA
- Type
- Privately Held
- Specialties
- asthma, cancer, and diabetes
Locations
-
Primary
Get directions
Charlottesville, VA 22901, US
Employees at Adovate
Updates
-
Grateful for Acumen Pharmaceuticals, Inc. and Daniel O'Connell for their continued efforts in advancing human health and keeping Charlottesville on the map in this important fight!
We are thrilled to extend our collaboration with Lonza to enable the potential future commercial launch of sabirnetug, our next-generation investigational treatment for Alzheimer’s disease that targets toxic soluble amyloid beta oligomers. Lonza will now manufacture cGMP drug product at their state-of-the-art facility in Visp, Switzerland for ongoing and future clinical phases and support our potential commercial launch of sabirnetug. They will also provide quality control and stability testing. Learn more about our collaboration in today’s press release: https://lnkd.in/gGSTffYy #AlzheimersDisease #ClinicalTrials #Lonza #AcumenPharmaceuticals
-
-
I am about to wrap up my first attendance to the BioHealth Capital Region Forum and Investor Conference. Thank you to Richard Bendis, Andy Eckert, M.S., Brett Shealy, John Newby and others for putting on this incredible event to bring the #DMV #biotech community together. The team at Adovate is thrilled to be part of this rapidly growing ecosystem. The presence of Gov. Wes Moore and Gov Glenn Youngkin further highlights the ongoing investments being made to support this vital sector. Thank you to everyone who is supporting Adovate's mission to improve patient care worldwide. #vabio #biopharma #biotech
-
-
Meet us at #BIO2024! Exciting developments at Adovate! As a pioneering pharmaceutical company, we're dedicated to creating best-in-class, novel drug candidates. Our focus? Adenosine receptors—a key player in major diseases like #asthma, #cancer, and #diabetes. Using our advanced adenosine drug development platform, we are designing and producing groundbreaking compounds with superior characteristics.
-